[Journal of Cosmetic Dermatology] Ultraviolet radiation B (UVB)-induced photoaging nude mice and human dermal fibroblasts were used as experimental models to investigate the therapeutic effects of cell-derived nanovesicles from hair follicle mesenchymal stem cells in photoaging models.

[Cell Death & Disease] Using a transgenic melanoma mouse model with a specific loss of AP2ε expression, researchers confirmed the impact of AP2ε to modulate the dynamic switch from a migratory to a proliferative phenotype.

[Clinical Cancer Research] Expression of G1/S-phase cell cycle regulators were evaluated alongside EGFR in breast cancer. The authors conjugated cetuximab with CDK inhibitor SNS-032, for specific delivery to EGFR-expressing cells and assessed antibody drug conjugate internalization, and its anti-tumor functions in vitro and in orthotopically-grown basal-like/TNBC xenografts.

[Cell Reports Medicine] The authors review the evolving treatment landscape of HER2-positive breast cancer, from the current approved therapies to the future perspectives, with a focus on the new agents which are likely to get approved in the next future.

[Edgewood Oncology] Edgewood Oncology announced that the first two patients with metastatic breast cancer were treated with BTX-A51, a multi-specific kinase inhibitor of casein kinase 1 alpha and cyclin-dependent kinases 7 and 9, that synergistically targets master regulators of cancer.

[Genentech, Inc.] Genentech announced that the US FDA has granted Breakthrough Therapy Designation for inavolisib, an investigational oral therapy, in combination with palbociclib and fulvestrant, for the treatment of adult patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment.

[SRI International] SRI’s Targeted Antigen Loaded Liposomes — a treatment that expands the benefits of immunotherapy such as check-point inhibitors — has been granted Orphan Drug Designation for PDAC by the US FDA.

[Walter and Eliza Hall Institute of Medical Research] An exceptional $8 million, 10-year philanthropic investment will spearhead new treatments for pancreatic cancer and create a new dedicated research centre at Walter and Eliza Hall Institute of Medical Research.

[Nature Communications] Investigators showed that SOX13 boosted protein remodeling of electron transport chain complexes by directly transactivating SCAF1. This led to increased supercomplex assembly, mitochondrial respiration, mitochondrial energetics and chemo- and immune-resistance.

[IRLAB Therapeutics] IRLAB Therapeutics AB announced that dosing has been initiated in a Phase I study of the drug candidate IRL757. IRL757 has been shown in preclinical disease models to counteract apathy – a condition that impairs the quality of life for millions of people with Parkinson’s disease and other CNS diseases.

[Advanced Science] A new single-cell patch-clamp/proteomics platform termed scPatch-Proteomics was developed on single neurons generated from hiPSCs bearing an Alzheimer's disease genetic mutation.

The multidomain collective dynamics on the trimer of the spike protein was analyzed using normal mode analysis. A common nanomechanical profile was identified in...